Sir,

The emergence of drug resistance among diarrheagenic *Escherichia coli* in the pediatric population is an important cause of morbidity and mortality in developing countries. The widespread reports\[[@ref1]\] of different mechanisms of drug resistance in *E. coli* not only complicates treatment of different infections caused by it, but also enhances the risks of transmission of these traits into bacteria of the same or other genus. This potential threat of spreading of drug resistance through transferrable genetic elements is complemented by the ability of *E. coli* to remain as intestinal commensal bacteria. The increasing importance of fecal carriage of *E. coli* as a source of drug resistant strain associated outbreaks has been widely reported.\[[@ref1]\] Proper knowledge of the current status of enteric carriage of resistant strains of *E. coli* and the antimicrobial susceptibility pattern of diarrhea causing strains in a given geographic location is a basic requirement toward adequate preventive measures. Unfortunately, indigenous data regarding both the drug resistance in diarrheagenic *E. coli* strains and also the incidence of gastrointestinal carriage of resistant strains is very limited. Such data is of immense importance in formulating the treatment protocol and hospital antimicrobial policy as well as outbreak control. Considering these facts, this study was initiated to establish the role of drug resistant *E. coli* existing either as normal flora or as a pathogen under different conditions responsible for further dissemination of antimicrobial resistance amongst different organisms.

Fecal samples were collected from patients presenting to pediatric outpatients department (community group) with diarrhea and compared with hospitalized pediatric patients with more than 72 h of hospital stay and concurrent intravenous antimicrobial therapy (hospitalized group) and control group of asymptomatic siblings of admitted pediatric patients of our tertiary care hospital between February 2013 and November 2013. 50 *E. coli* strain from each of the three study groups were isolated by standard protocol and were subjected to antimicrobial susceptibility testing as per the CLSI guidelines.\[[@ref2]\] ESBL producing strains of *E. coli* were screened by using ceftazidime and cefotaxime and phenotypically confirmed by double disk synergy test.\[[@ref3]\] *E. coli* strain ATTC 25922 was used as negative control and *Klebsiella pneumonia* strain ATCC 700603 as positive control.

All three groups showed a significant resistance to ampicillin, ceftazidime, piperacillin --- tazobactam, aztreonam and meropenem. Hospitalized patients outnumbered (100%) the community patients (86%) or the asymptomatic healthy children (90%) in their carriage of ESBLs, suggesting excessive use of antibiotics in the hospital settings. A significant higher hospital acquisition of ESBL producing *E. coli* has been reported in pediatric population from Madagascar and other developing countries.\[[@ref4]\] A hospital-based study on neonatal sepsis in Delhi a few years earlier showed that 50% of the causative gram negatives were ESBL producing *E. coli*.\[[@ref5]\]

Dissemination of ESBL producing clones resulting from movement of patients between community to hospital and intra- and inter-hospital not only promotes epidemic spread without any borders but also limits availability of treatments options for infections caused by such organism. Thus, there is an urgent need to promote a rational use of antibiotics, both in hospital and in the community, the development of new generic drugs, strict personal hygiene to prevent the selection and the spread of these strains and increase awareness among the population of the hazards of taking antibiotics without medical consultation.
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